Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Regeneron Pharmaceuticals is conducting a Phase 3 study titled ‘A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC).’ The study aims to evaluate the effectiveness of cemiplimab, an immune-boosting drug, compared to standard surgical procedures in treating early-stage CSCC. This research is significant as it explores a less invasive treatment option for a common skin cancer.
The intervention being tested is cemiplimab, a drug designed to enhance the immune system’s ability to target and destroy cancer cells by binding to the PD-1 protein on immune cells. The study compares this drug to the standard surgical approach.
The study is interventional with a randomized, parallel assignment model, focusing on treatment without masking. This means participants are randomly assigned to either the experimental group receiving cemiplimab or the control group undergoing standard surgical care.
The study began on January 2, 2025, with the latest update submitted on July 8, 2025. These dates are crucial as they indicate the study’s progress and current status, which is actively recruiting participants.
This study could impact Regeneron’s stock performance positively by potentially introducing a new treatment option for CSCC, enhancing their market position. Investors should watch for updates as successful results could shift market dynamics, especially in comparison to competitors focusing on similar cancer treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.